Association Between SNP of SP-D and Susceptibility and Prognosis of Infectious Keratitis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

145 participants

Study Classification

OBSERVATIONAL

Study Start Date

2016-10-01

Study Completion Date

2019-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study explores the association between single nucleotide polymorphism (Met11Thr) of surfactant protein D(SP-D) and susceptibility and prognosis of infectious keratitis.Met11Thr of SP-D of patients with keratitis and normal controls were compared.Allele and genotype frequencies of patients with keratitis and normal controls were determined by polymerase chain reaction with sequence specific primers(PCR-SSPs) .SP-D gene polymorphism of patients with keratitis and normal controls was detected by Sanger sequencing

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Microbiological Diagnosis of Infectious Keratitis to Pathogenic Fastidious Germs

NCT02819232

Infectious Keratitis

COMPLETED NA

Evaluation of the Corneal Endothelial Cell Layer by Specular Microscopy in Patients With Thyroid Eye Disease

NCT06235372

Thyroid Eye Disease

NOT_YET_RECRUITING

Study to Determine the Effect of Azasite on Corneal Surface Irregularity

NCT01797107

Meibomian Gland Dysfunction

WITHDRAWN PHASE2

Au-Ag-Cu2O NG With PTT Anti Drug-resistant Microbial Keratitis

NCT05268718

Keratitis, Ulcerative Antibiotic Resistance, Microbial Photothermal Therapy

UNKNOWN EARLY_PHASE1

[KSR-001-P01]Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristic of KSR-001

NCT05017870

Dry Eye Syndromes

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Surfactant protein D(SP-D) plays an important role in the innate immune system of the eye in the lacrimal duct, cornea and conjunctiva.The single lipopolysaccharide on the surface of bacteria and the receptors on the surface of immune cells are linked by SP-D ,which acts as a bridge to neutralize viruses in the innate immune defense system and assists other immune cells in clearing bacteria and fungi.SP-D can also participate in the acquired immune response after combining with lipopolysaccharide on the surface of microorganisms.Some single nucleotide polymorphisms of SP - D can not only affect the plasma level of SP - D, which leads to the differences of pathogen defense capability, but also can affect the space configuration and structure of carbohydrate recognition domain of SP-D, causing the change of ability of SP - D combined with pathogens to influence its defensive role.The concentration of SP - D in ocular surface is closely related to the occurrence and progression of infectious keratitis.Association between single nucleotide polymorphisms of SP-D and the occurrence and development of infectious keratitis has yet to be confirmed by research.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Infectious Keratitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Control Group

health volunteers

Sequencing

Intervention Type OTHER

polymerase chain reaction with sequence specific primers(PCR-SSP) and Sanger sequencing

Infectious Keratitis Group

Infectious corneal patients

Treatment of bacterial keratitis

Intervention Type DRUG

0.3% Levofloxacin Eye Drops or 0.3% Tobramycin Eye Drops QID

Treatment of fungal keratitis

Intervention Type DRUG

1% Fluconazole Eye Drops or 0.25% Amphotericin B Eye Drops QID

Treatment of viral keratitis

Intervention Type DRUG

0.1% Acyclovir eye drops QID ，Ganciclovir gel QN，Famiclovir tablets 0.25g TID

corneal scraping

Intervention Type DIAGNOSTIC_TEST

culture and sensitivity of corneal ulcerated infiltrating edge tissue

Sequencing

Intervention Type OTHER

polymerase chain reaction with sequence specific primers(PCR-SSP) and Sanger sequencing

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Treatment of bacterial keratitis

0.3% Levofloxacin Eye Drops or 0.3% Tobramycin Eye Drops QID

Intervention Type DRUG

Treatment of fungal keratitis

1% Fluconazole Eye Drops or 0.25% Amphotericin B Eye Drops QID

Intervention Type DRUG

Treatment of viral keratitis

0.1% Acyclovir eye drops QID ，Ganciclovir gel QN，Famiclovir tablets 0.25g TID

Intervention Type DRUG

corneal scraping

culture and sensitivity of corneal ulcerated infiltrating edge tissue

Intervention Type DIAGNOSTIC_TEST

Sequencing

polymerase chain reaction with sequence specific primers(PCR-SSP) and Sanger sequencing

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Clinical diagnosis of Infectious Keratitis.
* Laboratory diagnosis of Infectious Keratitis.

Exclusion Criteria

* Patients with topical or systemic long-term use of hormones, interferon, or immunosuppressive therapy.
* Patients with basic diseases such as diabetes, autoimmune disease, sjogren's syndrome, blepharitis, eyelid defect or incomplete eyelid closure.
* Patients with history of corneal myopia laser, cataract surgery and vitrectomy, or history of serious ocular trauma and drug allergies.

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes